WallStreetZenWallStreetZen

NYSEMKT: CLDI
Calidi Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CLDI stock forecasts and price targets.

Forecast return on equity

Is CLDI forecast to generate an efficient return?

Company
-1,383.66%
Industry
29.52%
Market
158.22%
CLDI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CLDI forecast to generate an efficient return on assets?

Company
-587.24%
Industry
3.78%
CLDI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CLDI earnings per share forecast

What is CLDI's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$5.68
Avg 2 year Forecast
-$4.90
Avg 3 year Forecast
-$4.77

CLDI revenue forecast

What is CLDI's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

CLDI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLDI$0.21N/AN/A
ADIL$1.55N/AN/A
ARTL$3.41N/AN/A
SLXN$0.63$6.00+850.87%Strong Buy
INM$0.70N/AN/A
View Top Biotech Stocks

Calidi Biotherapeutics Stock Forecast FAQ

What is CLDI's earnings growth forecast for 2026-2028?

(NYSEMKT: CLDI) Calidi Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 72.31%.

Calidi Biotherapeutics's earnings in 2026 is -$25,579,000.On average, 3 Wall Street analysts forecast CLDI's earnings for 2026 to be -$61,881,181, with the lowest CLDI earnings forecast at -$59,453,613, and the highest CLDI earnings forecast at -$63,700,767. On average, 3 Wall Street analysts forecast CLDI's earnings for 2027 to be -$53,345,470, with the lowest CLDI earnings forecast at -$51,253,490, and the highest CLDI earnings forecast at -$54,914,454.

In 2028, CLDI is forecast to generate -$52,011,833 in earnings, with the lowest earnings forecast at -$49,972,153 and the highest earnings forecast at -$53,541,593.

If you're new to stock investing, here's how to buy Calidi Biotherapeutics stock.

What is CLDI's revenue growth forecast for 2026-2028?

(NYSEMKT: CLDI) Calidi Biotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 51.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.83%.

Calidi Biotherapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast CLDI's revenue for 2026 to be $0, with the lowest CLDI revenue forecast at $0, and the highest CLDI revenue forecast at $0. On average, 3 Wall Street analysts forecast CLDI's revenue for 2027 to be $0, with the lowest CLDI revenue forecast at $0, and the highest CLDI revenue forecast at $0.

In 2028, CLDI is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is CLDI's forecast return on assets (ROA) for 2026-2028?

(NYSEMKT: CLDI) forecast ROA is -587.24%, which is lower than the forecast US Biotechnology industry average of 3.78%.

What is CLDI's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: CLDI) Calidi Biotherapeutics's current Earnings Per Share (EPS) is -$5.95. On average, analysts forecast that CLDI's EPS will be -$5.68 for 2026, with the lowest EPS forecast at -$5.46, and the highest EPS forecast at -$5.85. On average, analysts forecast that CLDI's EPS will be -$4.90 for 2027, with the lowest EPS forecast at -$4.70, and the highest EPS forecast at -$5.04. In 2028, CLDI's EPS is forecast to hit -$4.77 (min: -$4.59, max: -$4.91).

What is CLDI's forecast return on equity (ROE) for 2026-2028?

(NYSEMKT: CLDI) forecast ROE is -1,383.66%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.